Relay Therapeutics (RLAY) Institutional Ownership

During the previous two years, 184 institutional investors and hedge funds held shares of Relay Therapeutics. The most heavily invested institutionals were Vanguard Group Inc. ($61.92M), Bellevue Group AG ($52.23M), BVF Inc. IL ($43.71M), ArrowMark Colorado Holdings LLC ($42.94M), Casdin Capital LLC ($36.87M), Tang Capital Management LLC ($33.24M), and State Street Corp ($30.45M).Learn more on RLAY's institutional investors.

96.98% of Relay Therapeutics stock is owned by institutional investors. Learn more on RLAY's institutional investor holdings.

Of the 161 institutional investors that purchased Relay Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Norges Bank ($8.85M), Tang Capital Management LLC ($4.50M), Eventide Asset Management LLC ($2.68M), Millennium Management LLC ($2.43M), JPMorgan Chase & Co. ($2.29M), Bellevue Group AG ($2.05M), and Vanguard Group Inc. ($1.85M).

Institutional investors have bought a total of 58,123,920 shares in the last 24 months. This purchase volume represents approximately $406.09M in transactions.

Of the 71 institutional investors that sold Relay Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Price T Rowe Associates Inc. MD ($3.66M), FMR LLC ($1.78M), Marshall Wace LLP ($1.38M), Franklin Resources Inc. ($1.34M), Driehaus Capital Management LLC ($989.25K), Walleye Capital LLC ($892.85K), and Bank of America Corp DE ($794.03K).

Institutional investors have sold a total of 17,179,787 shares in the last 24 months. This volume of shares sold represents approximately $130.30M in transactions.